Mefloquine selectively increases asynchronous acetylcholine release from motor nerve terminals

Neuropharmacology

Volumn 50, Issue 3, 2006, Pages 345-353

  McArdle, Joseph J ^a,b   Sellin, Lawrence C ^a   Coakley, Kathleen M ^a   Potian, Joseph G ^a   Hognason, Kormakur ^a  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Asynchronous release; Mitochondria; Nerve terminal heterogeneity; Stimulus evoked transmitter release

Indexed keywords

ACETYLCHOLINE; CALCIUM CHANNEL; MEFLOQUINE; OLIGOMYCIN; THAPSIGARGIN;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CHOLINERGIC SYNAPSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; IN VITRO STUDY; MOUSE; MUSCLE INNERVATION; NERVE ENDING; NERVE POTENTIAL; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINE; ACTION POTENTIALS; ANIMALS; ANTIMALARIALS; CALCIUM; CHELATING AGENTS; DRUG INTERACTIONS; EGTAZIC ACID; ENZYME INHIBITORS; MEFLOQUINE; MICE; NEUROMUSCULAR JUNCTION; OLIGOMYCINS; PRESYNAPTIC TERMINALS; THAPSIGARGIN;

EID: 31844440834     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.09.011     Document Type: Article

References (40)

1. E. Alnaes, and R. Rahamimoff On the role of mitochondria in transmitter release from motor nerve terminals J. Physiol. 248 1975 285 306
2. S. Baudry, Y.T. Pham, B. Baune, S. Vidrequin, C. Crevoisier, F. Gimenez, and R. Farinotti Stereoselective passage of mefloquine through the blood-brain barrier in the rat J. Pharm. Pharmacol. 49 1997 1086 1090
3. +-depolarized motor nerve terminals containing compromised mitochondria J. Physiol. 532 2001 217 227
4. P. Camps, R. El Achab, D.M. Gorbig, J. Morral, D. Munoz-Torrero, A. Badia, J. Eladi Banos, N.M. Vivas, X. Barril, J. Orozco, and F.J. Luque Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease J. Med. Chem. 42 1999 3227 3242
5. C.J. Canfield, and R.S. Rozman Clinical testing of new antimalarial compounds Bull. World Health Organ. 50 1974 203 212
6. S.J. Cruikshank, M. Hopperstad, M. Younger, B.W. Connors, D.C. Spray, and M. Srinivas Potent block of Cx36 and Cx50 gap junction channels by mefloquine Proc. Natl. Acad. Sci. USA 101 2004 12364-12369
7. G. David Mitochondrial clearance of cytosolic Ca(2+) in stimulated lizard motor nerve terminals proceeds without progressive elevation of mitochondrial matrix [Ca(2+)] J. Neurosci. 19 1999 7495 7506
8. G. David, and E.F. Barrett Stimulation-evoked increases in cytosolic [Ca(2+)] in mouse motor nerve terminals are limited by mitochondrial uptake and are temperature-dependent J. Neurosci. 20 2000 7290 7296
9. G. David, and E.F. Barrett Mitochondrial Ca2+uptake prevents desynchronization of quantal release and minimizes depletion during repetitive stimulation of mouse motor nerve terminals J. Physiol. 548 2003 425 438
10. G. David, J.N. Barrett, and E.F. Barrett Evidence that mitochondria buffer physiological Ca2+ loads in lizard motor nerve terminals J. Physiol. 509 Pt 1 1998 59 65
11. G.S. Dow, T.H. Hudson, M. Vahey, and M.L. Koenig The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro Malaria J. 2 2003 14
12. S.J. Fuller, S. Naraqi, and G. Gilessi Paranoid psychosis related to mefloquine antimalarial prophylaxis P.N.G. Med. J. 45 2002 219 221
13. P.W. Gage, and R.S. Eisenberg Action potentials without contraction in frog skeletal muscle fibers with disrupted transverse tubules Science 158 1967 1702-1703
14. M. Geppert, Y. Goda, R.E. Hammer, C. Li, T.W. Rosahl, C.F. Stevens, and T.C. Sudhof Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse Cell 79 1994 717 727
15. F.M. Gribble, T.M. Davis, C.E. Higham, A. Clark, and F.M. Ashcroft The antimalarial agent mefloquine inhibits ATP-sensitive K-channels Br. J. Pharmacol. 131 2000 756 760
16. Hognason, K., Coakley, K., Rosenfeld, C., Sultatos, L.G., Sellin, L.C., McArdle, J.J., 2004. Mefloquine enhances spontaneous transmitter release and inhibits cholinesterase at the neuromuscular junction. Society for Neuroscience Abstracts 852.811.
17. H. Kollaritsch, J. Karbwang, G. Wiedermann, A. Mikolasek, K. Na-Bangchang, and W.H. Wernsdorfer Mefloquine concentration profiles during prophylactic dose regimens Wien. Klin. Wochenschr. 112 2000 441 447
18. H.S. Lee, and M.L. Go Effects of mefloquine on Ca2+ uptake and release by dog brain microsomes Arch. Int. Pharmacodyn. Ther. 331 1996 221 231
19. L.Y. Lim, and M.L. Go The anticholinesterase activity of mefloquine Clin. Exp. Pharmacol. Physiol. 12 1985 527 531
20. F.J. Lopez Antunano, and W.H. Wernsdorfer In vitro response of chloroquine-resistant Plasmodium falciparum to mefloquine Bull. World Health Organ. 57 1979 663 665
21. A.J. Martin-Galiano, B. Gorgojo, C.M. Kunin, and A.G. de la Campa Mefloquine and new related compounds target the F(0) complex of the F(0)F(1) H(+)-ATPase of Streptococcus pneumoniae Antimicrob. Agents Chemother. 46 2002 1680 1687
22. J.J. McArdle, and E.X. Albuquerque A study of the reinnervation of fast and slow mammalian muscles J. Gen. Physiol. 61 1973 1 23
23. J.J. McArdle, D. Angaut-Petit, A. Mallart, R. Bournaud, L. Faille, and J.L. Brigant Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena J. Neurosci. Methods 4 1981 109 115
24. McArdle, J.J., Sellin, L.C., 2003. Mefloquine (Lariam) increases spontaneous transmitter release from mature and immature motor nerve terminals. FASEB J. 17, A634 (abstract).
25. McArdle, J.J., Sellin, L.C., Coakley, K.M., Potian, J.G., Quinones-Lopez, M.C., Rosenfeld, C.A., Sultatos, L.G., Hognason, K., 2005. Mefloquine inhibits cholinesterases and alters cholinergic synaptic transmission. Neuropharmacology, in press.
26. N. Melamed-Book, and R. Rahamimoff The revival of the role of the mitochondrion in regulation of transmitter release J. Physiol. 509 Pt 1 1998 2
27. C.J. Ohnmacht, A.R. Patel, and R.E. Lutz Antimalarials. 7. Bis(trifluoromethyl)-β(2-piperidyl)-4-quinolinemethanols J. Med. Chem. 14 1971 926 928
28. W. Peters, J. Portus, and B.L. Robinson The chemotherapy of rodent malaria, XXVIII. The development of resistance to mefloquine (WR 142,490) Ann. Trop. Med. Parasitol. 71 1977 419 427
29. P.A. Phillips-Howard, and F.O. ter Kuile CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Safety 12 1995 370 383
30. E. Pous, J. Gascon, J. Obach, and M. Corachan Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject Trans. R. Soc. Trop. Med. Hyg. 89 1995 434
31. T.A. Ruff, S.J. Sherwen, and G.A. Donnan Seizure associated with mefloquine for malaria prophylaxis Med. J. Aust. 161 1994 453
32. Y. Sara, T. Virmani, F. Deak, X. Liu, and E.T. Kavalali An isolated pool of vesicles recycles at rest and drives spontaneous neurotransmission Neuron 45 2005 563 573
33. L.H. Schmidt, R. Crosby, J. Rasco, and D. Vaughan Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine) Antimicrob. Agents Chemother. 13 1978 1011 1030
34. J.A. Simpson, R. Price, F. ter Kuile, P. Teja-Isavatharm, F. Nosten, T. Chongsuphajaisiddi, S. Looareesuwan, L. Aarons, and N.J. White Population pharmacokinetics of mefloquine in patients with acute falciparum malaria Clin. Pharmacol. Ther. 66 1999 472 484
35. S. Suzuki, M. Osanai, N. Mitsumoto, T. Akita, K. Narita, H. Kijima, and K. Kuba Ca(2+)-dependent Ca(2+) clearance via mitochondrial uptake and plasmalemmal extrusion in frog motor nerve terminals J. Neurophysiol. 87 2002 1816 1823
36. J.D. Talbot, G. David, and E.F. Barrett Inhibition of mitochondrial Ca2+ uptake affects phasic release from motor terminals differently depending on external [Ca2+] J. Neurophysiol. 90 2003 491 502
37. S. Thesleff, L.C. Sellin, and S. Tagerud Tetrahydroaminoacridine (tacrine) stimulates neurosecretion at mammalian motor endplates Br. J. Pharmacol. 100 1990 487 490
38. M.M. van Riemsdijk, M.M. van der Klauw, J.A. van Heest, F.R. Reedeker, R.J. Ligthelm, R.M. Herings, and B.H. Stricker Neuro-psychiatric effects of antimalarials Eur. J. Clin. Pharmacol. 52 1997 1 6
39. T. Weinke, M. Trautmann, T. Held, G. Weber, D. Eichenlaub, K. Fleischer, W. Kern, and H.D. Pohle Neuropsychiatric side effects after the use of mefloquine Am. J. Trop. Med. Hyg. 45 1991 86 91
40. E. Wooltorton Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials C.M.A.J. 167 2002 1269 1270